However, current therapies focusing on the GH/IGF-1 axis are only effective in approximately 28%-50% of patients with acromegaly, while the remaining 50%-72% continue to experience excessive bone growth and/or abnormal bone metabolism, even after GHPA reduction or GH/IGF-1 level normalization (56–59). Here, GH1 is linked to acromegaly.